echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The first KRAS inhibitor license out!

    The first KRAS inhibitor license out!

    • Last Update: 2022-01-03
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Article source: Medical Rubik's Cube Info

    On November 30, Jimin Credential announced that its subsidiary Jiyu Pharmaceutical and Huya Biotechnology have reached an exclusive license agreement for the KRAS inhibitor JMKX1899


    According to the terms of the agreement, Jiyu Medicine will exclusively license the development, production and commercialization rights of the KRAS inhibitor JMKX1899 with independent intellectual property rights outside the Greater China Region to Huya, and the relevant rights and interests of JMKX1899 in the Greater China Region will remain with Jimin Trust.


    JMKX1899 is a KRAS inhibitor independently developed by the Small Molecule Innovation Center of Jiyu Medicine.


    KRAS mutations are widespread in tumor cells


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.